In vivo antibody therapy against ICAM1 or CD18 has been reported to inhibit diabetes-induced retinal leukostasis and endothelial injury in mice, suggesting that integrin/CAMs might make a good target for therapy [11,16,17]. The gene discussed is ITGB2; the disease is diabetes mellitus.